<?xml version='1.0' encoding='utf-8'?>
<document id="31030106"><sentence text="An alternating polarity switching assay for quantification of oxycodone and topiramate: An application of LC-MS/MS method in support to PK/PD study in rodents."><entity charOffset="62-71" id="DDI-PubMed.31030106.s1.e0" text="oxycodone" /><entity charOffset="76-86" id="DDI-PubMed.31030106.s1.e1" text="topiramate" /><pair ddi="false" e1="DDI-PubMed.31030106.s1.e0" e2="DDI-PubMed.31030106.s1.e0" /><pair ddi="false" e1="DDI-PubMed.31030106.s1.e0" e2="DDI-PubMed.31030106.s1.e1" /></sentence><sentence text="In mass spectrometry, compounds that have different ionization properties experience challenges in simultaneous analysis" /><sentence text=" In the present paper, the authors proposed a polarity switching (+ve and -ve) LC-MS/MS method to analyze oxycodone and topiramate in a single run"><entity charOffset="106-115" id="DDI-PubMed.31030106.s3.e0" text="oxycodone" /><entity charOffset="120-130" id="DDI-PubMed.31030106.s3.e1" text="topiramate" /><pair ddi="false" e1="DDI-PubMed.31030106.s3.e0" e2="DDI-PubMed.31030106.s3.e0" /><pair ddi="false" e1="DDI-PubMed.31030106.s3.e0" e2="DDI-PubMed.31030106.s3.e1" /></sentence><sentence text=" The developed method was validated in the range of 5-1000 ng/mL for oxycodone and 20-5000 ng/mL for topiramate as per the US FDA guidelines"><entity charOffset="69-78" id="DDI-PubMed.31030106.s4.e0" text="oxycodone" /><entity charOffset="101-111" id="DDI-PubMed.31030106.s4.e1" text="topiramate" /><pair ddi="false" e1="DDI-PubMed.31030106.s4.e0" e2="DDI-PubMed.31030106.s4.e0" /><pair ddi="false" e1="DDI-PubMed.31030106.s4.e0" e2="DDI-PubMed.31030106.s4.e1" /></sentence><sentence text=" The mass spectrometer was operated in multiple reaction monitoring (MRM) mode to analyze oxycodone and topiramate simultaneously using oxycodone-d6 and topiramate-d12 as internal standards, respectively"><entity charOffset="90-99" id="DDI-PubMed.31030106.s5.e0" text="oxycodone" /><entity charOffset="104-114" id="DDI-PubMed.31030106.s5.e1" text="topiramate" /><entity charOffset="136-148" id="DDI-PubMed.31030106.s5.e2" text="oxycodone-d6" /><entity charOffset="153-167" id="DDI-PubMed.31030106.s5.e3" text="topiramate-d12" /><pair ddi="false" e1="DDI-PubMed.31030106.s5.e0" e2="DDI-PubMed.31030106.s5.e0" /><pair ddi="false" e1="DDI-PubMed.31030106.s5.e0" e2="DDI-PubMed.31030106.s5.e1" /><pair ddi="false" e1="DDI-PubMed.31030106.s5.e0" e2="DDI-PubMed.31030106.s5.e2" /><pair ddi="false" e1="DDI-PubMed.31030106.s5.e0" e2="DDI-PubMed.31030106.s5.e3" /><pair ddi="false" e1="DDI-PubMed.31030106.s5.e1" e2="DDI-PubMed.31030106.s5.e1" /><pair ddi="false" e1="DDI-PubMed.31030106.s5.e1" e2="DDI-PubMed.31030106.s5.e2" /><pair ddi="false" e1="DDI-PubMed.31030106.s5.e1" e2="DDI-PubMed.31030106.s5.e3" /><pair ddi="false" e1="DDI-PubMed.31030106.s5.e2" e2="DDI-PubMed.31030106.s5.e2" /><pair ddi="false" e1="DDI-PubMed.31030106.s5.e2" e2="DDI-PubMed.31030106.s5.e3" /></sentence><sentence text=" Sample preparation was performed in 96-well protein precipitation plates using acetonitrile"><entity charOffset="80-92" id="DDI-PubMed.31030106.s6.e0" text="acetonitrile" /></sentence><sentence text=" Processed samples were analyzed using a C18 column with a gradient mobile phase composed of 10 mm ammonium formate with 0"><entity charOffset="99-115" id="DDI-PubMed.31030106.s7.e0" text="ammonium formate" /></sentence><sentence text="1% formic acid and acetonitrile"><entity charOffset="3-14" id="DDI-PubMed.31030106.s8.e0" text="formic acid" /><entity charOffset="19-31" id="DDI-PubMed.31030106.s8.e1" text="acetonitrile" /><pair ddi="false" e1="DDI-PubMed.31030106.s8.e0" e2="DDI-PubMed.31030106.s8.e0" /><pair ddi="false" e1="DDI-PubMed.31030106.s8.e0" e2="DDI-PubMed.31030106.s8.e1" /></sentence><sentence text=" The method was validated for selectivity, specificity, linearity, precision and accuracy, dilution integrity and stability" /><sentence text=" After validation, this method was successfully applied to quantify oxycodone and topiramate in plasma of concomitantly treated Sprague Dawley (SD) rats"><entity charOffset="68-77" id="DDI-PubMed.31030106.s10.e0" text="oxycodone" /><entity charOffset="82-92" id="DDI-PubMed.31030106.s10.e1" text="topiramate" /><pair ddi="false" e1="DDI-PubMed.31030106.s10.e0" e2="DDI-PubMed.31030106.s10.e0" /><pair ddi="false" e1="DDI-PubMed.31030106.s10.e0" e2="DDI-PubMed.31030106.s10.e1" /></sentence><sentence text="" /></document>